company background image
CRSP

CRISPR Therapeutics NasdaqGM:CRSP Stock Report

Last Price

US$56.34

Market Cap

US$4.4b

7D

7.9%

1Y

-51.2%

Updated

21 May, 2022

Data

Company Financials +
CRSP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

CRSP Stock Overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

CRISPR Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share PriceUS$56.34
52 Week HighUS$169.76
52 Week LowUS$42.51
Beta2.04
1 Month Change1.46%
3 Month Change-3.35%
1 Year Change-51.25%
3 Year Change52.27%
5 Year Change274.60%
Change since IPO299.86%

Recent News & Updates

Shareholder Returns

CRSPUS BiotechsUS Market
7D7.9%1.4%-2.7%
1Y-51.2%-21.7%-12.9%

Return vs Industry: CRSP underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: CRSP underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is CRSP's price volatile compared to industry and market?
CRSP volatility
CRSP Average Weekly Movement11.1%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CRSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CRSP's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013473Sam Kulkarnihttps://www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

CRISPR Therapeutics Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
CRSP fundamental statistics
Market CapUS$4.36b
Earnings (TTM)US$311.61m
Revenue (TTM)US$915.36m

14.0x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRSP income statement (TTM)
RevenueUS$915.36m
Cost of RevenueUS$496.96m
Gross ProfitUS$418.41m
Other ExpensesUS$106.80m
EarningsUS$311.61m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.02
Gross Margin45.71%
Net Profit Margin34.04%
Debt/Equity Ratio0%

How did CRSP perform over the long term?

See historical performance and comparison

Valuation

Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


14x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: CRSP ($56.34) is trading above our estimate of fair value ($0.85)

Significantly Below Fair Value: CRSP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CRSP is good value based on its PE Ratio (14x) compared to the US Biotechs industry average (15.1x).

PE vs Market: CRSP is good value based on its PE Ratio (14x) compared to the US market (15.3x).


Price to Earnings Growth Ratio

PEG Ratio: CRSP is good value based on its PEG Ratio (0.2x)


Price to Book Ratio

PB vs Industry: CRSP is overvalued based on its PB Ratio (1.9x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


57.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRSP's forecast earnings growth (57.9% per year) is above the savings rate (1.9%).

Earnings vs Market: CRSP's earnings (57.9% per year) are forecast to grow faster than the US market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CRSP's revenue (52.7% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: CRSP's revenue (52.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRSP is forecast to be unprofitable in 3 years.


Past Performance

How has CRISPR Therapeutics performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


36.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CRSP has high quality earnings.

Growing Profit Margin: CRSP became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CRSP has become profitable over the past 5 years, growing earnings by 36.4% per year.

Accelerating Growth: CRSP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CRSP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CRSP's Return on Equity (13.9%) is considered low.


Financial Health

How is CRISPR Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CRSP's short term assets ($2.3B) exceed its short term liabilities ($113.7M).

Long Term Liabilities: CRSP's short term assets ($2.3B) exceed its long term liabilities ($247.6M).


Debt to Equity History and Analysis

Debt Level: CRSP is debt free.

Reducing Debt: CRSP had no debt 5 years ago.

Debt Coverage: CRSP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CRSP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRSP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Sam Kulkarni (42 yo)

4.42yrs

Tenure

US$17,037,015

Compensation

Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Centessa Pharmaceuticals Lim...


CEO Compensation Analysis

Compensation vs Market: Sam's total compensation ($USD17.04M) is above average for companies of similar size in the US market ($USD6.86M).

Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CRSP's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: CRSP's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

CRISPR Therapeutics AG's employee growth, exchange listings and data sources


Key Information

  • Name: CRISPR Therapeutics AG
  • Ticker: CRSP
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$4.364b
  • Shares outstanding: 77.46m
  • Website: https://www.crisprtx.com

Number of Employees


Location

  • CRISPR Therapeutics AG
  • Baarerstrasse 14
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.